Life Science Leader — April 2013 Outsourcing and the oral solid dose: Will challenges lead to new patterns of outsourcing? Life Science Leader — CRO Leadership Awards supplement issue Strategic Outsourcing Often Means Combining Functional and Full-Service CROs 
 
May 10 Life Science Leader's May issue includes results from Nice Insight annual research April 10 Learn about Trends in Outsourcing the Oral Solid Dose in April's Outsourcing Insights 
"Business intelligence is crucial in the decision-making process of
pharmaceutical and biopharmaceutical companies as they increase their levels
of external development and manufacturing. It also is vitally important for
contract service providers in evaluating their competitive advantage. Nice
Insight’s data facilitates that knowledge for the players in pharmaceutical
outsourcing. At Pharmaceutical Technology, we also use their research to
spot and track the trends we write about."
Michelle Hoffman Editorial Director,Pharmaceutical Drug Development and Manufacturing Group, Advanstar Pharmaceutical  
Pharma Chem Outsourcing 2013
September 16-18 Long Branch, NJ |
Almac Group, Ltd. BioVectra, Inc. Dr. Reddy's Laboratories Ltd. Lonza CMC Biologics Enzon Pharmaceuticals, Inc.
Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the research and development of therapeutics for cancer patients with high unmet medical needs. The company’s drug-development programs utilize two platforms: Customized PEGylation Linker Technology and third-generation mRNA-targeting agents utilizing Locked Nucleic Acid technology. The company has four compounds in human clinical development and multiple novel mRNA antagonists in preclinical research. It receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its proprietary Customized Linker Technology. http://www.enzon.com
Regions
Americas Stock Symbol Private Filter of Enzon Pharmaceuticals, Inc.'s services per Nice Insight Categories
Contact Enzon Pharmaceuticals, Inc. 
|
|
|
